United States - English - NLM (National Library of Medicine)

terumo bct, ltd - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 4% w/v anticoagulant solution usp is intended for use only for the anticoagulation of whole blood as part of automated apheresis procedures. [see dosage and administration (2).] do not infuse sodium citrate 4% w/v anticoagulant solution usp directly to the donor. sodium citrate 4% w/v anticoagulant solution usp has not been adequately studied in controlled clinical trials with specific populations.

United States - English - NLM (National Library of Medicine)

csl plasma inc. - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - anticoagulant sodium citrate 4% w/v solution usp is intended for use only for the anticoagulation of whole blood as part of automated apheresis procedures. [see dosage and administration (2).] do not infuse anticoagulant sodium citrate 4% w/v solution usp directly to the donor. anticoagulant sodium citrate 4% w/v solution usp has not been adequately studied in controlled clinical trials with specific populations.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dexamethasone sodium phosphate, quantity: 4.37 mg/ml (equivalent: dexamethasone phosphate, qty 4 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; sodium citrate dihydrate; water for injections; sodium sulfite; disodium edetate; hydrochloric acid - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in: acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy; relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available; primary and secondary adrenocortical insufficiency. disease therapy dexamethasone is indicated for therapy of the following diseases: collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy. pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency. blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia. rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis. skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis. gastrointestinal disorders: ulcerative colitis, regional enteritis. oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis). eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy. neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children. endocrine disorders: adrenal insufficiency. preoperative and postoperative support dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery. shock dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - dexamethasone sodium phosphate, quantity: 4.37 mg/ml (equivalent: dexamethasone phosphate, qty 4 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; sodium citrate dihydrate; water for injections; creatinine - replacement therapy - adrenocortical insufficiency dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in: acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy; relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with sur

United States - English - NLM (National Library of Medicine)

citra labs llc - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - anhydrous citric acid 14 g in 30 ml - tricitrasol ® anticoagulant sodium citrate concentrate, 46.7% trisodium citrate, is an anticoagulant used in granulocytapheresis procedures (granulocyte collection by apheresis). just prior to performing granulocytapheresis, aseptically add 30 ml of tricitrasol ® to 500 ml of the 6% solution of hydroxyethyl starch (hes), e.g. hespan ® 2-8 . agitate the resultant solution for 1 minute to assure a uniform concentration of anticoagulant. the resultant solution of tricitrasol ® and 6% solution of hes contains the following concentration depending upon the volume used: the tricitrasol ® /hes solution is stable for up to 24 hours at room temperature after mixing. refer to the manufacturer's operator's manual of the apheresis medical device for the directions to perform the granulocytapheresis procedure. not for direct intravenous infusion.

United States - English - NLM (National Library of Medicine)

terumo bct, ltd - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 4% w/v anticoagulant solution is intended for use only for the anticoagulation of whole blood as part of automated apheresis procedures. [see dosage and administration (2).] do not infuse sodium citrate 4% w/v anticoagulant solution usp directly to the donor. sodium citrate 4% w/v anticoagulant solution usp has not been adequately studied in controlled clinical trials with specific populations.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 100 mg/ml; disodium edetate, quantity: 60 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, constipation, headache, leg cramps, black stools, oliguria, stupor, convulsions, palsies and coma. chronic lead poisoning causes variable involvement of the central n

Australia - English - Department of Health (Therapeutic Goods Administration)

piramal critical care pty ltd - fentanyl citrate, quantity: 78.5 microgram/ml (equivalent: fentanyl, qty 50 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride - sublimaze is indicated for analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises; use as a narcotic analgesic supplement in general and regional anaesthesia; administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - disodium edetate, quantity: 30 mg/ml - injection, concentrated - excipient ingredients: water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code) 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, cons

Australia - English - Department of Health (Therapeutic Goods Administration)

southern xp ip pty ltd - dexamethasone sodium phosphate, quantity: 4.37 mg (equivalent: dexamethasone phosphate, qty 4 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; creatinine; sodium citrate; disodium edetate - replacement therapy - adrenocortical insufficiency,dexamethasone has predominantly glucocorticoid activity and therefore is not a complete replacement therapy in cases of adrenocortical insufficiency. dexamethasone should be supplemented with salt and/or a mineralocorticoid, such as deoxycorticosterone. when so supplemented, dexamethasone is indicated in:,? acute adrenocortical insufficiency - addison's disease, bilateral adrenalectomy;,? relative adrenocortical insufficiency - prolonged administration of adrenocortical steroids can produce dormancy of the adrenal cortex. the reduced secretory capacity gives rise to a state of relative adrenocortical insufficiency which persists for a varying length of time after therapy is discontinued. should a patient be subjected to sudden stress during this period of reduced secretion (for up to two years after therapy has ceased) the steroid output may not be adequate. steroid therapy should therefore be reinstituted to help cope with stress such as that associated with surgery, trauma, burns, or severe infections where specific antibiotic therapy is available;,? primary and secondary adrenocortical insufficiency.,disease therapy,dexamethasone is indicated for therapy of the following diseases:,collagen diseases: systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, giant cell arteritis, adjunctive therapy for short-term administration during an acute episode or exacerbation, acute rheumatic carditis ? during an exacerbation or as maintenance therapy.,pulmonary disorders: status asthmaticus, chronic asthma, sarcoidosis, respiratory insufficiency.,blood disorders: leukaemia, idiopathic thrombocytopaenic purpura in adults, acquired (autoimmune) haemolytic anaemia.,rheumatic diseases: rheumatoid arthritis, osteoarthritis, adjunctive therapy for short-term administration during an acute episode or exacerbation of rheumatoid arthritis or osteoarthritis.,skin diseases: psoriasis, erythema multiforme, pemphigus, neutrophilic dermatitis, localised neurodermatitis, exfoliative dermatitis, sarcoidosis of skin, severe seborrhoeic dermatitis, contact dermatitis.,gastrointestinal disorders: ulcerative colitis, regional enteritis.,oedema: cerebral oedema associated with primary or metastatic brain tumours, neurosurgery or stroke, oedema associated with acute non-infectious laryngospasm (or laryngitis).,eye disorders: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, chorioretinitis, optic neuritis, anterior ischaemic optic neuropathy.,neoplastic states: cerebral neoplasms, hypercalcaemia associated with cancer, leukaemias and lymphomas in adults, acute leukaemia in children.,endocrine disorders: adrenal insufficiency.,preoperative and postoperative support,dexamethasone may be used in any surgical procedure when the adrenocortical reserve is doubtful. this includes the treatment of shock due to excessive blood loss during surgery.,shock,dexamethasone may be used as an adjunct in the treatment of shock. dexamethasone should not be used as a substitute for normal shock therapy.